All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How can advances in polycythemia vera research help us to better understand AML?

During the Acute Leukemia Forum 2021, the AML Hub spoke to Jerry L. Spivak, Johns Hopkins University, Baltimore, US. We asked, How can advances in polycythemia vera research help us to better understand AML?

How can advances in polycythemia vera research help us to better understand AML?

Polycythemia vera is a clonal disorder that has proven to be a useful model in the context of advancing knowledge surrounding AML. In this video, Spivak discusses lessons to be learned from polycythemia vera regarding chemotherapy, novel therapy targets, and gene mutations that can be translated into the AML setting.

 

Share:
More about...